5/9/2025

The U.S. Attorney's Office for the Southern District of New York last week announced the resolution of two significant False Claims Act cases—one from a large settlement and the other the result of...

Source: Finnhub

5/9/2025

Biotech ETFs face sharp declines, but strong operational momentum in select companies offers investment opportunities.

Source: SeekingAlpha

5/9/2025

Source: SeekingAlpha

5/9/2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

Source: Yahoo

5/8/2025

The trial is aimed at assessing long-term efficacy as well as safety of the therapy in 150 chronic HDV patients.

Source: Yahoo

5/8/2025

Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to ensure our medicines are delivered in ways that...

Source: Finnhub

5/8/2025

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the U.S. and internationally. The 52-week range of Gilead Sciences stock price was $62.07 to ...

Source: Yahoo

5/8/2025

Hartford Dividend and Growth Fund (I Share) outperformed the S&P 500 Index for the quarter. Read more here.

Source: SeekingAlpha

5/7/2025

Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining other drugmakers that have promised to bolster domestic capabilities as they brace for tariffs from the Trump administration. Johnson & Johnson, Merck and Novartis are among the companies that have made investment pledges for the coming years, with an aggregate total of more than $200 billion. The administration is currently conducting an investigation into potential tariffs on the pharmaceutical industry.

Source: Yahoo

5/7/2025

Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital investment and job creation. The latest initiative will further grow the company’s presence in the U.S., which currently hosts Gilead’s largest research, development, and manufacturing footprint globally.

Source: Yahoo

5/7/2025

The new investments, unveiled on Wednesday, will supplement an already planned spending of $21 billion to boost U.S. manufacturing and research and development through 2030, the drugmaker said. These investments will be used for new technology, building three new facilities and upgrading three existing sites, it said. Major U.S. drugmakers, including Eli Lilly, Johnson & Johnson, Merck and Bristol Myers Squibb, have also recently announced additional investments to boost domestic production amid the tariff threat.

Source: Yahoo

5/7/2025

U.S. President DonaldTrump is expected to sign an executive order as early as nextweek that would revive an effort to decrease drug costs by tyingthe amount the government pays for some medicines...

Source: Finnhub

5/7/2025

Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the company also reported Q1 financial results, announced positive outcomes for Trodelvy in cancer treatment, and shared updates on strategic partnerships, all highlighting its ongoing innovation. Despite these developments, Gilead's share price saw a minor 1.78% decline, in line with a flat market...

Source: Yahoo

5/7/2025

Gilead Sciences announced $11billion in new planned investment in the U.S. to boost itsdomestic manufacturing and research heft, becoming the latestcompany to announce spending plans in reaction to...

Source: Finnhub

5/7/2025

Gilead Sciences Inc: * GILEAD TO INVEST $32 BILLION IN U.S. MANUFACTURING ANDRESEARCHAND DEVELOPMENT THROUGH 2030 AND CREATE MORE THAN 3,000 DIRECTAND INDIRECT JOBS BY 2028 ...

Source: Finnhub

5/7/2025

2024 also saw some changes to some of my holdings as the author shuttled several dividend income payers for higher return crypto plays. Click to read.

Source: SeekingAlpha

5/7/2025

FOSTER CITY, Calif., May 07, 2025--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained undet

Source: Yahoo

5/7/2025

FOSTER CITY, Calif., May 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and stat

Source: Yahoo

5/7/2025

Source: SeekingAlpha

5/6/2025

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors

Source: MarketWatch